Form 4: Eli Lilly Director Acquires 12 Shares of Common Stock Through Deferral Plan

Director Ralph Alvarez acquired 12 shares of Eli Lilly common stock through a deferral plan, at a price of $950.46 per share.

Summary

• Ralph Alvarez, a director at Eli Lilly & Co, acquired 12 shares of common stock on July 15, 2024.
• The shares were acquired at a price of $950.46 each.
• This transaction was part of the Lilly Directors' Deferral Plan, where the shares were deferred in lieu of cash compensation.
• The shares will be settled in common stock after Mr. Alvarez's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally neutral to positive. The director's acquisition of shares can be seen as a sign of confidence in the company.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to director compensation and is common in publicly traded companies.

Comparison to Industry Standards

• Director stock acquisitions are a common form of compensation in publicly traded companies like Eli Lilly.
• Many companies offer deferral plans as part of their compensation packages, similar to the Lilly Directors' Deferral Plan.
• The price of $950.46 per share reflects the market value of LLY stock at the time of the transaction, which is consistent with standard practice.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates director confidence in the company.

Key Dates

Keywords

Eli Lilly, LLY, Director, Stock Acquisition, Deferral Plan, Form 4, Insider Trading